Themis Medicare (BOM:530199) 3-Year RORE % : -69.91% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:530199 Themis Medicare Ltd BOM:530199
69 GF Score
Price ₹113.00
GF Value ₹148.85
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Themis Medicare 3-Year RORE %?

Themis Medicare BOM:530199 +3.01% 69 3-Year RORE % is -69.91 as of Mar. 2026. GuruFocus rates BOM:530199 with a GF Score™ of 69/100 and a GF Value™ of ₹148.85 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 945 Drug Manufacturers companies, Themis Medicare ranks worse than 86.46% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Themis Medicare's 3-Year RORE % for the quarter that ended in Mar. 2026 was -69.91%.

The industry rank for Themis Medicare's 3-Year RORE % or its related term are showing as below:

BOM:530199's 3-Year RORE % is ranked worse than
86.46% of 945 companies
in the Drug Manufacturers industry
Industry Median: 3.06 vs BOM:530199: -69.91

Themis Medicare  (BOM:530199) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Themis Medicare 3-Year RORE % Related Terms


Themis Medicare 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Themis Medicare's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Themis Medicare 3-Year RORE % Chart

Themis Medicare Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 37.54 13.54 -18.37 -23.18 -69.91

Themis Medicare Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -23.18 -78.58 -123.11 -104.13 -69.91

BOM:530199 vs ZTS: 3-Year RORE % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Themis Medicare's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Themis Medicare 3-Year RORE % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Themis Medicare's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Themis Medicare's 3-Year RORE % falls into.


BOM:530199
69GF Score
Themis Medicare Ltd BOM:530199
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Themis Medicare 3-Year RORE % Calculation

Themis Medicare's 3-Year RORE % for the quarter that ended in Mar. 2026 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( 0.12-4.72 )/( 8.08-1.5 )
=-4.6/6.58
=-69.91 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of -69.91 mean?
Themis Medicare (BOM:530199) has a 3-Year RORE % of -69.91 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Themis Medicare and its competitors. According to the industry distribution chart, Themis Medicare ranks #817 out of 945 companies in the Drug Manufacturers industry, placing it in the top 86.5%.
Is Themis Medicare's 3-Year RORE % too high?
Themis Medicare's current 3-Year RORE % is -69.91. Based on the distribution chart, Themis Medicare ranks #817 out of 945 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Themis Medicare has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Themis Medicare's 3-Year RORE % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Themis Medicare ranks #817 out of 945 companies for 3-Year RORE %. This places Themis Medicare in the lower half of its industry. The industry median 3-Year RORE % is 3.06. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Drug Manufacturers company?
The median 3-Year RORE % among Drug Manufacturers companies is 3.06, based on 945 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Themis Medicare and its competitors. For the Drug Manufacturers industry, the median 3-Year RORE % is 3.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Themis Medicare's current 3-Year RORE % is -69.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Themis Medicare stock overvalued right now?
Based on GuruFocus' analysis, Themis Medicare (BOM:530199) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹148.85, compared to a current price of ₹113.00 — trading 24.1% below its estimated fair value. The current 3-Year RORE % is -69.91. Themis Medicare's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Themis Medicare (BOM:530199), the current 3-Year RORE % is -69.91 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Themis Medicare (BOM:530199) Overvalued in 2026?

Based on GuruFocus' analysis, Themis Medicare stock appears to be undervalued. The current stock price of ₹113.00 is trading 24.1% below its estimated GF Value™ of ₹148.85. GuruFocus considers Themis Medicare to be Modestly Undervalued.

Key valuation signals for BOM:530199:

  • 3-Year RORE %: -69.91
  • GF Value™: ₹148.85 vs. price of ₹113.00 (24.1% below fair value)
  • GF Score™: 69/100 with 5 warning signs

No single metric tells the full story. See the BOM:530199 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Themis Medicare Business Description

Other Exchanges THEMISMED:India
Address Swami Vivekanand Road, 11/12, Udyog Nagar Industrial Estate, Goregaon (West), Mumbai, MH, IND, 400 104
Themis Medicare Ltd is an Indian based company engaged in the manufacturing and marketing of pharmaceutical products. The Company operates only in one business segment which is Pharmaceuticals. Geographically, it derives a majority of revenue from India and also has a presence in the international market. Its product categories include Anti Malarial, CCD products, Nutritional Gummies, and Candy and Other Products such as OD-LM, Dexem, Medzol and Tazowin.
69GF Score

Get the complete analysis for BOM:530199

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹113.00
Price
₹148.85
GF Value